Multi-Center GENFI Study Validates NfL as a Reliable Biomarker in Genetic FTD Research

Linnemann C, Wilke C, Mengel D, et al. NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study

Journal of Neurology, Neurosurgery & Psychiatry Published Online First: 19 January 2024. doi: 10.1136/jnnp-2023-332464

Summary

A multi-center study lead by Drs. Christoph Linnemann and Matthis Synofzik evaluates blood neurofilament light chain (NfL) as a biomarker for genetic frontotemporal dementia (gFTD) in multi-center trials. They examine NfL's lab-to-lab reliability, stage stratification capability in gFTD, comparability between blood matrices, and stability across recruiting sites. Analysis of 344 samples from a gFTD cohort shows high consistency and reliability of NfL across different labs, effectiveness in distinguishing gFTD stages, and robustness across multiple sites. The teams findings support NfL's suitability as a biomarker in gFTD multi-center trials.

Use the link below to read more.

https://doi.org/10.1136/jnnp-2023-332464